annb0t
Top 20
MELBOURNE, Australia, Oct. 17, 2024 /PRNewswire/ --Â Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3 2024). (PRNewsfoto/Telix Pharmaceuticals Limited)
Revenue update, full year guidance reaffirmed
Unaudited total revenue of approximately US$135 million (AU$201 million[1]), primarily generated from sales of Telix's prostate cancer imaging product Illuccix® in the Pre...
>>> Read more: Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
Revenue update, full year guidance reaffirmed
Unaudited total revenue of approximately US$135 million (AU$201 million[1]), primarily generated from sales of Telix's prostate cancer imaging product Illuccix® in the Pre...
>>> Read more: Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
